Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1

Inclusion Criteria: * Age between ≥16 and ≤70 years at screening, no gender restrictions * ECOG score of 0-1 at screening * Newly diagnosed Ph-negative B-ALL, MRD positive(bone marrow MRD ≥0.01% by flow cytometry) in CR1 (with \<5% blasts in bone marrow, no blasts in peripheral blood, no extramedullary disease)after induction chemotherapy or consolidation chemotherapy. * Newly diagnosed Ph-positive B-ALL, MRD positive(bone marrow MRD ≥0.01% by flow cytometry or BCR-ABL1 \>0.01% detected by qPCR) in CR1 (with \<5% blasts in bone marrow, no blasts in peripheral blood, no extramedullary disease) . * At diagnosis of B-ALL,CD19 expression of leukemic cells is positive by flow cytometry in bone marrow or peripheral blood. * Appropirate organ function, meeting the following criteria: 1. Aspartate aminotransferase (AST) ≤3 times the upper limit of normal (ULN); 2. Alanine aminotransferase (ALT) ≤3 times ULN; 3. Total bilirubin ≤2 times ULN (for patients with Gilbert's syndrome, total bilirubin ≤3.0 times ULN and direct bilirubin ≤1.5 times ULN); 4. Serum creatinine ≤1.5 times ULN, or creatinine clearance ≥60 mL/min (using the Cockcroft-Gault formula); 5. International Normalized Ratio (INR) ≤1.5 times ULN and activated partial thromboplastin time (APTT) ≤1.5 times ULN; 6. Left ventricular ejection fraction (LVEF) ≥50%; 7. Minimum pulmonary reserve, with oxygen saturation \>91% on room air; * Meets leukapheresis standard of the study center, with no contraindications for blood cell separation; * Voluntarily agrees to participate in this study and signs on the informed consent form(ICF). Exclusion Criteria: * Received CAR-T cell therapy before screening; * Inherited bone marrow failure syndrome(IBMFS) or any other known bone marrow failure syndromes; * Active systemic autoimmune diseases requiring treatment; * Any of the following conditions: 1. HBsAg and/or HBeAg positive; 2. HBe-Ab and/or HBc-Ab positive with HBV-DNA levels above the lower limit of quantification; 3. HCV-Ab positive; 4. TP-Ab positive; 5. HIV antibody positive; 6. EBV-DNA or CMV-DNA levels above the lower limit of quantification; * Active infection at screening. * Any other malignancy within the past five years before screening, excluding cases where the patient has been disease-free for more than 5 years after curative treatment or has a low risk of relapse as assessed by the investigator; * Any of the following cardiac conditions: 1. NYHA Class III or IV congestive heart failure; 2. Severe arrhythmia requiring treatment; 3. Uncontrolled hypertension or pulmonary hypertension despite standard therapy; 4. Unstable angina; 5. Myocardial infarction, bypass surgery, or stent placement within six months before cell retransfusion; 6. Clinically significant valvular disease; 7. Other cardiac conditions deemed unsuitable by the investigator; * History of epilepsy, cerebellar disease, or other active central nervous system disorders; * Uncontrolled diabetes; * History of symptomatic deep vein thrombosis or pulmonary embolism within six months before screening that is not well controlled; * History of hypersensitivity to any component of the investigational product. * Received a live vaccine within six weeks before screening; * Life expectancy of less than three months; * Participation in another interventional clinical trial and receiving investigational drugs within three months (for unapproved drugs) or within five half-lives (for approved drugs) before cell infusion, or plans to participate in another clinical trial or receive anti-cancer therapy outside the study protocol during the study period; * Other conditions deemed unsuitable for participation in this clinical trial by the investigator.